Equity Overview
Price & Market Data
Price: $0.751
Daily Change: -$0.0159 / 2.12%
Range: $0.74 - $0.787
Market Cap: $25,232,256
Volume: 55,240
Performance Metrics
1 Week: -8.46%
1 Month: 92.46%
3 Months: 176.2%
6 Months: 56.05%
1 Year: -75.94%
YTD: 44.35%
Company Details
Employees: 17
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.